Your Search for 'Target Product Profiles : Physician Insights on Key Attributes - Alzheimer''s Disease (Moderate to Severe)' returned 5 results - Page 1 of 1
Datamonitor, March 2009, Pages: 185
by physician-estimated diagnoses, diseaseseverity, drug-treated population and drug-class usage in the US, 2008 11
Figure 2: Preferred biologic drug brands by line of therapy in moderate to severe psoriasis
GlobalData, April 2011, Pages: 63
and efficacy profiles which are diseasetargeting.
Strong Pipeline Candidates are expected to Intensify Future Competition
The authors research found that there are currently 20 products in different
Datamonitor, March 2010, Pages: 124
pipeline treatments.
-Identification of key opportunities and threats facing developers of treatments for spinal cord injury.
-Insight from four internationally recognized key opinion leaders in the field
GlobalData, June 2011, Pages: 55
attributed to the increase in treatment-seeking behavior and disease awareness and the increasing use of off-label drugs, although no major pipeline products are estimated to be launched in the forecast period
GlobalData, March 2011, Pages: 65
by technologically advanced products possessing improved safety and efficacy profiles which are diseasetargeting. The only available prescription drug, Restasis, has proven its success as is evident by the increasing
